Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prenetics Global (PRE) EBITDA (2021 - 2025)

Historic EBITDA for Prenetics Global (PRE) over the last 5 years, with Q3 2025 value amounting to -$7.4 million.

  • Prenetics Global's EBITDA rose 3609.94% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.7 million, marking a year-over-year increase of 456.19%. This contributed to the annual value of -$18.0 million for FY2024, which is 12312.68% down from last year.
  • According to the latest figures from Q3 2025, Prenetics Global's EBITDA is -$7.4 million, which was up 3609.94% from -$12.4 million recorded in Q2 2025.
  • Prenetics Global's EBITDA's 5-year high stood at $4.4 million during Q4 2022, with a 5-year trough of -$148.4 million in Q2 2022.
  • For the 5-year period, Prenetics Global's EBITDA averaged around -$27.1 million, with its median value being -$12.4 million (2025).
  • Examining YoY changes over the last 5 years, Prenetics Global's EBITDA showed a top increase of 10517.02% in 2022 and a maximum decrease of 185360.5% in 2022.
  • Over the past 5 years, Prenetics Global's EBITDA (Quarter) stood at -$84.5 million in 2021, then skyrocketed by 105.17% to $4.4 million in 2022, then tumbled by 523.51% to -$18.5 million in 2023, then increased by 2.87% to -$18.0 million in 2024, then surged by 58.77% to -$7.4 million in 2025.
  • Its EBITDA stands at -$7.4 million for Q3 2025, versus -$12.4 million for Q2 2025 and -$10.9 million for Q1 2025.